Tsalta
Tsalta
Sex: F
Data Quality: 3 stars
MS: 3 yrs
Type: Relapsing-Remitting
Sensation: Moderate
Overall: Mild
Cognition: moderate
Vision: mild
Speech: none
Swallowing: none
Upper limb: moderate
Walking: mild
Tsalta
Female, 44 years
Altamont, NY
Primary Condition
MS
Type
Relapsing-Remitting
First symptom
Oct 2008
Diagnosis
Jan 2009
See more

Treatment charts require Flash. If you have problems installing Flash, visit the FAQ for help.

Get Adobe Flash player

Tsalta's Rebif is for:

  • MS

Tsalta has not reported any side effects for Rebif.

Tsalta's Rebif History (Ongoing)
Rebif (interferon beta-1a subq injection)
As needed Feb 24 - Mar 10, 2009
3 x 22 mcg/0.5 mL Weekly Mar 10 - 25, 2009
3 x 44 mcg/0.5 mL Weekly Mar 25 - 25, 2009
3 x 44 mcg/0.5 mL Weekly Mar 25 - 25, 2009
3 x 44 mcg/0.5 mL Weekly Mar 25, 2009 - Last Update
Evaluations
Date Dosage MS (Multiple Sclerosis) Efficacy Side Effects Adherence Burden
Jul 29, 2011 3 x 44 mcg/0.5 mL Weekly ? NoneNoneNoneNone AlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at all
Jun 15, 2010 3 x 44 mcg/0.5 mL Weekly ? NoneNoneNoneNone AlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at all
May 21, 2010 3 x 44 mcg/0.5 mL Weekly ? NoneNoneNoneNone AlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at all
Oct 29, 2009 3 x 44 mcg/0.5 mL Weekly ? NoneNoneNoneNone AlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at all
Sep 23, 2009 3 x 44 mcg/0.5 mL Weekly ? NoneNoneNoneNone AlwaysAlwaysAlwaysAlways Not at allNot at allNot at allNot at all
Date
Jun 15, 2010
Advice & Tips
I do my shots Sun, Tues, Thurs. After the first 6 months or so I had no more reactions at all. I can do the shot and then do whatever I had planned. I find that doing the shot freehand is much easier after the initial shock of actually sticking the needle in goes by. Now it is just something I do.
Cost
< $25 monthly

About Rebif (Prescription Drug)

Rebif, a brand name for interferon beta-1a, is an immunomodulator used to prevent episodes of symptoms and slow the development of disability in patients with relapsing-remitting multiple sclerosis. It is given subcutaneously (under the skin) three times a week, ideally the same 3 days each week.

Learn more about Rebif in our Rebif Community Report.